2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Endocrine
2
Breast
1
Conditions
Breast Neoplasms
228
Neoplasm Metastasis
19
Neoplasms
9
Breast Neoplasms, Male
7
Breast Diseases
7
Ovarian Neoplasms
4
Carcinoma, Intraductal, Noninfiltrating
4
Recurrence
3
Obesity
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Arthralgia
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexuality
1
Interventions
Fulvestrant
5
Exercise
5
Eating
5
Standard of Care
3
Sodium Chloride
3
Diet
3
Alpelisib
3
ribociclib
2
gallium Ga 68 dotatate
2
exemestane
2
Vitamin D
2
Tamoxifen
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ethanol
2
Blood Specimen Collection
2
Anastrozole
2
zopiclone
1
ziprasidone
1
veliparib
1
testosterone undecanoate
1
testosterone enanthate
1
pazopanib
1
mirabegron
1
methyl hydroxyethyl cellulose
1
lenvatinib
1
fluorocholine
1
evolocumab
1
dimethandrolone-undecanoate
1
cyclopropapyrroloindole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Endocrine Neoplasia Type 1
×
exemestane
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT02753686
2023-02-15
Treat ER+ight
Novartis
Completed
440 enrolled